KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Non-Current Debt (2017 - 2019)

Xenon Pharmaceuticals (XENE) has disclosed Non-Current Debt for 3 consecutive years, with $10.9 million as the latest value for Q4 2019.

  • On a quarterly basis, Non-Current Debt changed N/A to $10.9 million in Q4 2019 year-over-year; TTM through Dec 2019 was $10.9 million, a N/A change, with the full-year FY2019 number at $10.9 million, changed N/A from a year prior.
  • Non-Current Debt was $10.9 million for Q4 2019 at Xenon Pharmaceuticals, down from $11.8 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $15.1 million in Q1 2019 to a low of $5.5 million in Q1 2018.
  • A 3-year average of $11.2 million and a median of $11.8 million in 2018 define the central range for Non-Current Debt.
  • Biggest YoY gain for Non-Current Debt was 176.46% in 2019; the steepest drop was 20.82% in 2019.
  • Xenon Pharmaceuticals' Non-Current Debt stood at $6.1 million in 2017, then skyrocketed by 143.87% to $14.9 million in 2018, then dropped by 26.85% to $10.9 million in 2019.
  • Per Business Quant, the three most recent readings for XENE's Non-Current Debt are $10.9 million (Q4 2019), $11.8 million (Q3 2019), and $13.2 million (Q2 2019).